Molecular imaging: High-resolution detectors for early diagnosis and therapy monitoring of breast cancer

2006 ◽  
Vol 569 (2) ◽  
pp. 286-290 ◽  
Author(s):  
F. Garibaldi ◽  
E. Cisbani ◽  
S. Colilli ◽  
F. Cusanno ◽  
R. Fratoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Imaging ◽  
High Resolution ◽  
Early Diagnosis ◽  
Therapy Monitoring ◽  
Diagnosis And Therapy

scholarly journals Methylated septin 9 gene for noninvasive diagnosis and therapy monitoring of breast cancer

2018 ◽  
Vol 7 (3) ◽  
pp. 587-599 ◽  
Author(s):  
Shen Chen ◽  
Changxin Zhou ◽  
Wei Liu ◽  
Shanping Sun ◽  
Anqi Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Therapy Monitoring ◽  
Noninvasive Diagnosis ◽  
Septin 9 ◽  
Diagnosis And Therapy

scholarly journals Targeting breast cancer exosomes with nucleic aptamers: innovative tools for early diagnosis and therapy

2021 ◽  
Author(s):  
C.L. Esposito ◽  
◽  
C Quintavalle ◽  
F Ingenito ◽  
D Rotoli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Clinical Utility ◽  
Rna Aptamers ◽  
Innovative Strategies ◽  
Diagnosis And Therapy ◽  
Proteomic Approach ◽  
Promising Target ◽  
Associated Proteins ◽  
Target Cancer

Exosomes are emerging as promising target for early diagnosis and therapy in diff erent oncological conditions including breast cancer (BC). However, the development of tools able to easily and specifi cally target cancer cell-derived exosomes still represent a fundamental issue that is required to realize their clinical utility. Nucleic-acid aptamers are a promising class of structured single stranded oligonucleotides that serve as high affi nity ligands of disease-associated proteins. Given their high potential in diagnosis and therapy, we addressed the development of aptamers specifi c for BC-derived exosomes. To this end, we developed a novel SELEX strategy by using exosomes purifi ed from primary BC cells as positive selection target. By such a strategy we isolated nuclease resistant RNA aptamers able to specifi cally discriminate BC-derived exosomes from those produced by normal cells. Th e best sequences were optimized identifying short molecules (about 30-35 mer) that was characterized as tools for exosome detection. Further, we demonstrated that the developed aptamers inhibited exosome cellular uptake antagonizing cancer exosome-induced cell migration. By proteomic approach we identifi ed possible targets that we are characterizing. Our results underline the great potential of isolated aptamers as tools for the development of innovative strategies for BC early diagnosis and therapy.

scholarly journals Molecular Imaging Probes for Diagnosis and Therapy Evaluation of Breast Cancer

2013 ◽  
Vol 2013 ◽  
pp. 1-14 ◽  
Author(s):  
Qingqing Meng ◽  
Zheng Li
Keyword(s):  
Breast Cancer ◽  
Molecular Imaging ◽  
Cancer Biology ◽  
Hormone Receptors ◽  
Receptor Imaging ◽  
Therapy Evaluation ◽  
Diagnosis And Therapy ◽  
Molecular Imaging Probes ◽  
Imaging Probes

Breast cancer is a major cause of cancer death in women where early detection and accurate assessment of therapy response can improve clinical outcomes. Molecular imaging, which includes PET, SPECT, MRI, and optical modalities, provides noninvasive means of detecting biological processes and molecular eventsin vivo.Molecular imaging has the potential to enhance our understanding of breast cancer biology and effects of drug action during both preclinical and clinical phases of drug development. This has led to the identification of many molecular imaging probes for key processes in breast cancer. Hormone receptors, growth factor receptor, and angiogenic factors, such as ER, PR, HER2, and VEGFR, have been adopted as imaging targets to detect and stage the breast cancer and to monitor the treatment efficacy. Receptor imaging probes are usually composed of targeting moiety attached to a signaling component such as a radionuclide that can be detected using dedicated instruments. Current molecular imaging probes involved in breast cancer diagnosis and therapy evaluation are reviewed, and future of molecular imaging for the preclinical and clinical is explained.

scholarly journals MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Mustafa Kahraman ◽  
Anne Röske ◽  
Thomas Laufer ◽  
Tobias Fehlmann ◽  
Christina Backes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Early Stage ◽  
Therapy Monitoring ◽  
Diagnosis And Therapy

scholarly journals Molecular Imaging-Guided Interventional Hyperthermia in Treatment of Breast Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Yurong Zhou ◽  
Jihong Sun ◽  
Xiaoming Yang
Keyword(s):  
Breast Cancer ◽  
Molecular Imaging ◽  
Early Diagnosis ◽  
Targeted Therapies ◽  
Response Assessment ◽  
Chemotherapeutic Drugs ◽  
Effective Management ◽  
Surgical Indications ◽  
Recent Advances

Breast cancer is the most frequent malignancy in women worldwide. Although it is commonly treated via chemotherapy, responses vary among its subtypes, some of which are relatively insensitive to chemotherapeutic drugs. Recent studies have shown that hyperthermia can enhance the effects of chemotherapy in patients with refractory breast cancer or without surgical indications. Recent advances in molecular imaging may not only improve early diagnosis but may also facilitate the development and response assessment of targeted therapies. Combining advanced techniques such as molecular imaging and hyperthermia-integrated chemotherapy should open new avenues for effective management of breast cancer.

scholarly journals Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
E. Wehrse ◽  
S. Sawall ◽  
L. Klein ◽  
P. Glemser ◽  
S. Delorme ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Resolution ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Therapy Monitoring ◽  
Photon Counting ◽  
Case Series ◽  
Single Photons ◽  
Breast Cancer Patients ◽  
Conventional Ct

AbstractConventional CT scanners use energy-integrating detectors (EIDs). Photon-counting detector (PCD) computed tomography (CT) utilizes a CT detector technology based on smaller detector pixels capable of counting single photons and in addition discriminating their energy. Goal of this study was to explore the potential of higher spatial resolution for imaging of bone metastases. Four female patients with histologically confirmed breast cancer and bone metastases were included between July and October 2019. All patients underwent conventional EID CT scans followed by a high resolution non-contrast experimental PCD CT scan. Ultra-high resolution (UHR) reconstruction kernels were used to reconstruct axial slices with voxel sizes of 0.3 mm × 0.3 mm (inplane) × 1 mm (z-direction). Four radiologists blinded for patient identity assessed the images and compared the quality to conventional CT using a qualitative Likert scale. In this case series, we present images of bone metastases in breast cancer patients using an experimental PCD CT scanner and ultra-high-resolution kernels. A tendency to both a smaller inter-reader variability in the structural assessment of lesion sizes and in the readers’ opinion to an improved visualization of lesion margins and content was observed. In conclusion, while further studies are warranted, PCD CT has a high potential for therapy monitoring in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document